Clopidogrel versus ticagrelor or prasugrel after primary PCI according to CYP2C19 genotype: a POPular Genetics subanalysis

Claassens et al. POPular Genetics CYP2C19 analysis

Daniel M.F. Claassens[1,2], M.D.*, Thomas O. Bergmeijer[1], M.D.*, Gerrit J.A. Vos[1], M.D., Renicus S. Hermanides[2], M.D., Ph.D., Arnoud W.J. van 't Hof[2,3,4,5] M.D., Ph.D., Pim van der Harst[6,7], M.D., Ph.D., Emanuele Barbato[8,9], M.D., Ph.D., Carmine Morisco[8], M.D., Ph. D., Richard M. Tjon Joe Gin[10], M.D., Folkert W. Asselbergs[7,11,12], M.D., Ph.D., Arend Mosterd[13], M.D., Ph.D., Jean-Paul R. Herrman[14], M.D., Ph.D., Willem J.M. Dewilde[15], M.D., Ph.D., Paul W.A. Janssen[1], M.D., Ph.D., Johannes C. Kelder[1], M.D., Ph.D., Bakhtawar K. Mahmoodi[1], M.D., Ph.D., M.P.H., Vera H.M. Deneer[16,17], Pharm.D., Ph.D., Jurriën M. ten Berg[1,5], M.D., Ph.D.

* Both authors contributed equally to this work

1. Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands

2. Department of Cardiology, Isala Hospital, Zwolle, The Netherlands

3. Department of Cardiology, University Medical Center Maastricht, Maastricht, The Netherlands

4. Department of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands

5. Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands

6. Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands

7. Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

8. Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy

9. Cardiovascular Research Center, Onze lieve Vrouwe Hospital, Aalst, Belgium

10. Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands

11. Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, United Kingdom;

12. Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom

13. Department of Cardiology, Meander Medical Center, Amersfoort, The Netherlands

14. Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands

15. Department of Cardiology, Imelda hospital, Bonheiden, Belgium.

16. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

17. Department of Clinical Pharmacy, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands

Corresponding author:

Jurriën M. ten Berg, MD, PhD, FESC, FACC

Department of cardiology

St. Antonius Hospital and CARIM, Maastricht

Koekoekslaan 1, 3435CM, Nieuwegein

2

The Netherlands

Tel: +31 88 320 13 82

Email: jurtenberg@gmail.com

Subject terms:

Genetics, pharmacology, coronary artery disease, thrombosis, clinical studies

Word count: 4921

Background

Guidelines favor ticagrelor or prasugrel over clopidogrel in patients with myocardial infarction. However, the POPular Genetics trial showed that in primary percutaneous coronary intervention (PCI) patients, a *CYP2C19* genotype-guided strategy was associated with a lower bleeding risk without increasing thrombotic risk, compared to routine ticagrelor/prasugrel treatment. Nevertheless, optimal $P2Y_{12}$ inhibitor treatment in specific *CYP2C19* genetic subgroups is still subject of debate.

Methods

A pre-specified subanalysis of the POPular Genetics trial was performed, using patients in whom *CYP2C19*2, *3 and *17 genotype was determined. Two different analyses were planned. The first assessed the effect of the *CYP2C19*17 allele in clopidogrel treated patients. The second compared the effect of clopidogrel in noncarriers of a loss-of-function allele with ticagrelor/prasugrel treated patients, irrespective of *CYP2C19* genotype. Main outcomes were a thrombotic outcome (cardiovascular death, myocardial infarction, stent thrombosis and stroke), and a bleeding outcome (PLATO major and minor bleeding), after 12 months.

Results

A total of 2,429 patients were used for analyses. In the first analysis, the *CYP2C19*17 polymorphism was not found to have a significant influence on thrombotic (adjusted hazard ratio (adjHR) 0.95 95% confidence interval (CI) 0.45 – 2.02) or bleeding outcomes (adjHR 0.74, 95%CI 0.48 – 1.18). In the second analysis, clopidogrel was associated with a lower number of bleeding events compared to ticagrelor/prasugrel (9.9% vs. 11.7%, adjHR 0.74, 95%CI 0.56 – 0.96), without a significant increase in thrombotic events (3.4% vs 2.5%, adjHR 1.14, 95%CI 0.68 – 1.90).

4

Conclusions

In primary PCI patients not carrying a *CYP2C19* loss-of-function allele, the use of clopidogrel compared to ticagrelor or prasugrel was associated with lower bleeding rates, without an increase in thrombotic events. No effect on clinical outcomes was found for the *CYP2C19**17 polymorphism.

Trial registration:

Clinicaltrials.gov: NCT01761786; https://www.trialregister.nl/: NTR number NL2872

Keywords: myocardial infarction, acute coronary syndrome, genotyping, P2Y12, genetic testing

Non-standard abbreviations and acronyms:

KASP: kompetitive allele specific

LoF: Loss-of-function

PLATO: Platelet Inhibition and Patient Outcomes

POPular Genetics: Patient Outcomes after Primary PCI

Tailor PCI: Tailored Antiplatelet Therapy Following PCI

TRITON TIMI: Trial To Assess Improvement in Therapeutic Outcomes by Optimizing

Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction

What is known:

- Guidelines favor ticagrelor and prasugrel over clopidogrel in myocardial infarction patients due to a lower thrombotic risk, albeit a higher bleeding risk.
- There is a wide variability in platelet reactivity in clopidogrel treated patients, which can partially be explained by variations in the *CYP2C19* gene.

What the study adds:

- Carrying one or more *CYP2C19**17 allele has no effect on clinical outcomes in ST-elevation myocardial infarction (STEMI) patients.
- In STEMI patients not carrying a *CYP2C19* loss-of-function allele, clopidogrel was associated with a reduction in bleeding- without increasing thrombotic events compared to ticagrelor and prasugrel.

Introduction

Dual antiplatelet therapy, consisting of aspirin and a $P2Y_{12}$ inhibitor, remains the cornerstone of antithrombotic treatment in patients with myocardial infarction. Guidelines favor ticagrelor and prasugrel, because these showed a reduction in thrombotic events as compared to clopidogrel.[1,2] This higher efficacy, however, is hampered by a higher bleeding risk.[3,4]

Clopidogrel is a prodrug, transformed into its active metabolite by hepatic cytochrome P450 enzymes in the liver. There is a large variability in antiplatelet effect in patients treated with clopidogrel, which in part can be explained by genetic variations in the *CYP2C19* gene.[5] Patients carrying a *CYP2C19**2 or *3 loss-of-function (LoF) allele are at higher risk for having high on-treatment platelet reactivity when treated with clopidogrel, which is associated with a higher risk of stent thrombosis and recurrent atherothrombotic events.[6,] In patients carrying a *CYP2C19**17 gain-of-function allele, clopidogrel efficacy might be better, with possibly higher bleeding rates.[7,8] However, data on the influence of *CYP2C19**17 on clinical outcome are conflicting and mostly derived from observational studies.[9] Its clinical relevance is therefore not clear.

In the recently published Patient Outcome after Primary Percutaneous Coronary Intervention (PCI) (POPular Genetics) trial, a *CYP2C19* genotype guided antiplatelet strategy, using clopidogrel in patients without LoF allele and ticagrelor or prasugrel in patients carrying one or more LoF alleles, showed a reduction in bleeding risk (defined as Platelet Inhibition and Patient Outcomes (PLATO) major or minor bleeding) compared to standard treatment with ticagrelor or prasugrel, without an increase in thrombotic risk.[10] Moreover, in a subanalysis of the PLATO trial, ticagrelor was not superior to clopidogrel regarding the thrombotic outcome.[11] Since then, thrombotic event rates have declined considerably.[12] At the same time,

7

the incidence of bleeding events, which are associated with a substantial morbidity and mortality risk, remained high.[13] Therefore, the question of which antiplatelet strategy is best to balance thrombotic and bleeding risk in ST-elevation myocardial infarction (STEMI) patients after primary PCI is still open, in particular for different subgroups of noncarriers of *CYP2C19* LoF alleles.

In this pre-specified subanalysis of the POPular Genetics trial we study the effect of the *CYP2C19**17 allele in clopidogrel treated patients and the safety and efficacy of clopidogrel in patients without a LoF allele, compared to ticagrelor and prasugrel.

Methods

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Study design

The detailed design and results of the POPular Genetics trial have been reported previously.[10,14] In brief; POPular Genetics was an open-label, randomized, multicenter trial with 2,488 STEMI patients undergoing primary PCI. It compared a standard treatment with ticagrelor or prasugrel with a *CYP2C19* genotype-guided strategy, where patients received clopidogrel if they did not carry a *CYP2C19**2 or *3 LoF allele, and ticagrelor or prasugrel if they were carrier of such a LoF allele. Treatment and follow-up duration were 12 months. An institutional review board approved the trial and all participants provided informed consent.

8

Blood samples were collected from patients in both treatment groups. During the trial, *CYP2C19* genotyping was performed in the genotype-guided group, where the presence of the *CYP2C19**2 and *3 polymorphism was determined using the Spartan RX point-of-care system or the TaqMan StepOnePlus assay. After the trial was completed, genotyping was performed in all patients in the standard treatment arm, and both groups were tested for *CYP2C19**17. This was done by LGC Biosearch Technologies (Hoddesdon, United Kingdom) using a kompetitive allele specific (KASP) genotyping assay. For the analyses, an intention to treat-analysis was performed in which patients were divided in a clopidogrel or ticagrelor/prasugrel treated group, based on the drug prescribed at discharge. Two different analyses were performed. The first analysis compared clopidogrel in *CYP2C19**1/*1 patients with clopidogrel in patients with a *1/*17 or *17/*17 genotype. No separate analysis for homozygous *CYP2C19**17 carriers was performed, because of the low number of patients in this group (n=35). The second analysis compared clopidogrel treated patients not carrying a *CYP2C19**2 or *3 LoF allele with ticagrelor or prasugrel treated patients irrespective of their CYP2C19 metabolizer status. In addition, we performed two sensitivity analyses, one including only patients without LoF alleles in both the clopidogrel and ticagrelor or prasugrel treated group and one on-treatment analysis.

Statistical analysis

This pre-specified subanalysis was not prospectively powered and is based on the number of patients in the original trial of whom the *CYP2C19* genetic profile was available. The outcomes were a thrombotic outcome consisting of cardiovascular death, myocardial infarction, stent thrombosis and stroke, a bleeding outcome consisting of PLATO major and minor bleeding, and the individual components of the thrombotic and bleeding outcome. The

9

definitions were identical to those used in the POPular Genetics trial.[10] All outcomes were adjudicated by a blinded event committee.

Variables are presented as numbers (percentages) and means ± standard deviation. Missing baseline variables were not imputed. P-values were calculated using Student's t-test for continuous variables, chi-square tests for categorical variables and one-way ANOVAs for variables with multiple categories. A p-value below 0.05 was considered statistically significant. Kaplan-Meier curves were estimated and the log-rank test was used to calculate p-values. If a patient was lost to follow-up, it was censored after the last known contact. Cox proportional hazard models were used to calculate hazard ratios (HR) and the 95% confidence intervals (CI). The Efron approximation was used to handle ties. To adjust for possible confounders, all baseline characteristics with a p-value < 0.10 were selected for univariate regression analysis. If there was a significant interaction (p < 0.05) in the univariate analysis, they were selected for multivariable regression analysis. The final model included only those characteristics with a significant interaction in the multivariable analysis. Main effects were included in the model. All analyses were performed using R version 3.6.0.

Results

Figure 1 shows a flow chart of how the subgroups were selected. In the POPular Genetics cohort, *CYP2C19**2, *3 and *17 carrier status was available in 2,100 patients, of which 1,550 did not carry a LoF allele. In the remaining 388 patients *CYP2C19* carrier status was unknown. Of these 388 patients, 329 were treated with ticagrelor or prasugrel and could therefore be included in the ticagrelor/prasugrel group of the second analysis. Of the 1,550 patients not carrying a LoF allele, 821 were treated with clopidogrel and 729 with ticagrelor

10

or prasugrel. Of the 821 clopidogrel treated patients, 277 had a *1/*17 genotype and 35 patients had a *17/*17 genotype. The baseline characteristics for the two analyses can be found in Tables 1 and 2. All groups were well balanced in baseline characteristics, except for the more common use of proton pump inhibitors and oral anticoagulation in the clopidogrel treated patients as compared to the ticagrelor or prasugrel treated patients. Tables S1 and S2 in the supplementary appendix show what variables were used in univariate and multivariate regression analysis and what variables were used in the final model.

Effect of the *CYP2C19*17* allele in clopidogrel treated patients

For this analysis, 420 patients with a *CYP2C19*1/*1 genotype and 312 patients with a *CYP2C19*1/*17 or *17/*17 genotype were available. An overview of the outcomes is presented in Table 3. There were no significant differences between the patients with *CYP2C19*1/*1 genotype versus carriers of a *17 allele for the combined thrombotic outcome (3.8% vs. 3.8%, adjHR 0.95, 95%CI 0.45 – 2.02, p = 0.90) (Figure 2A) and the combined bleeding outcome (11.2% vs 9.3%, adjHR 0.74, 95%CI 0.48 – 1.18, p = 0.21) (Figure 2B).

Clopidogrel in patients not carrying a *CYP2C19*2 or *3* allele versus ticagrelor or prasugrel irrespective of *CYP2C19* genotype

For this analysis, 821 clopidogrel and 1,608 ticagrelor or prasugrel treated patients were available. Table 4 shows an overview of the outcomes. There was no significant differences in the combined thrombotic outcome (3.4% vs. 2.5%, adjHR 1.14, 95%CI 0.68 – 1.90, p = 0.62) (Figure 3A), while the combined bleeding outcome occurred significantly less frequently in clopidogrel treated patients (9.9% vs. 11.7%, HR 0.74, 95%CI 0.56 – 0.96, p = 0.03) (Figure 3B).

11

Sensitivity analyses

Results for the two sensitivity analyses are presented in Table 5. The first analysis included 1,550 patients without LoF allele, of which 821 patients were treated with clopidogrel and 729 with ticagrelor or prasugrel. The adjusted HR for the combined thrombotic outcome was 1.11 (95%CI 0.61 – 2.03, p = 0.72), while the adjusted HR for the combined bleeding outcome was 0.59 (95%CI 0.44 – 0.80, p <0.001). The on-treatment analysis included the 821 clopidogrel treated patients and 1,613 ticagrelor or prasugrel treated patients. The adjusted HR for the combined thrombotic outcome was 0.98 (95%CI 0.56 – 1.70, p = 0.94), while the adjusted HR for the combined bleeding outcome was 0.68 (95%CI 0.52 – 0.90, p = 0.008).

Discussion

In this pre-specified subanalysis of the POPular Genetics trial, which included STEMI patients who underwent primary PCI and compared clopidogrel treated noncarriers of *CYP2C19* LoF alleles with all ticagrelor and prasugrel treated patients, treatment with clopidogrel was associated with a significantly lower bleeding rate compared to treatment with ticagrelor or prasugrel. This finding held true in both the sensitivity analyses. The effect was primarily driven by a reduction of PLATO minor bleeding. There was no association found between clopidogrel use and a higher risk for the combined thrombotic outcome, although the number of patients with a recurrent myocardial infarction was numerically higher in clopidogrel treated patients. These findings match the outcomes of the overall POPular Genetics trial.[10] Also in the PLATO genetic subanalysis, in which 3,554 ticagrelor-treated patient without *CYP2C19* LoF allele were compared to 3,516 clopidogrel-treated patients without *CYP2C19* LoF allele, similar to our second sensitivity analysis, the event rate

12

for a combined thrombotic outcome consisting of cardiovascular death, myocardial infarction

and stroke was only numerically lower with the use of ticagrelor, not reaching statistical

significance (8.8% vs 10.0%, HR 0.86 (0.74-1.01), p = 0.06).[11] This in contrast to the overall

PLATO trial, which showed clear benefit in reducing thrombotic risk with ticagrelor

compared to clopidogrel, at the cost of increased non-CABG related major bleeding rates.[3]

Nevertheless, the treatment effect in the PLATO subanalysis was almost similar to that of the

main trial, so the lack of statistical significance could also have been due to a lack of power.

With respect to the use of prasugrel, a genetic subanalysis of the Trial To Assess

Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-

Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 trial did not provide a direct

comparison between prasugrel and clopidogrel in different *CYP2C19* genetic subgroups, but

did conclude that clopidogrel treated patients have significantly worse outcomes when

carrying a LoF allele compared to noncarriers, which was not found in prasugrel treated

patients.[15]

The primary analysis of the Tailored Antiplatelet Therapy Following PCI (TAILOR-PCI) trial

included only patients who were carriers of *2 or *3 LoF alleles.[16] It compared 903 patients in

a *CYP2C19* genotype-guided group, thus treated with ticagrelor, to 946 patients in a

conventional therapy group, treated with clopidogrel, who were genotyped at the end of the

follow-up period. The primary composite endpoint of cardiovascular death, myocardial

infarction, stroke, stent thrombosis and recurrent ischemia at 12 months, occurred less

frequently in patients treated with ticagrelor, but without reaching statistical significance (4%

vs 5.9%, HR 0.66 (0.43-1.02), p =0.056). Based on the results of these trials, one might

conclude that in the absence of a *CYP2C19* LoF allele, the balance in net clinical benefit ends

up equal for clopidogrel versus ticagrelor, albeit with a somewhat lower bleeding risk with

13

clopidogrel and somewhat lower thrombotic risk with ticagrelor. In clinical practice, bleeding and thrombotic risk should be weighted to choose the optimal treatment strategy for the individual patient.

Furthermore, we studied the effect of the *CYP2C19**17 gain-of-function polymorphism in clopidogrel treated patients. This allele has been associated with higher enzyme activity, increased platelet inhibition and an increased risk for bleeding, which was also found in the genetics subanalysis of the PLATO trial.[11,17] The evidence, however, is conflicting. A meta-analysis performed by Li *et al.*, containing data from 11 studies, found the *CYP2C19**17 allele to be associated with less atherothrombotic events in patients treated with clopidogrel (based on 6 studies), while an increased risk for bleeding events was found (based on 4 studies).[8] Comparable results were found in a meta-analysis performed by Zabalza *et al.*[18] A meta-analysis performed by Bauer *et al.*, however, did not find any significant interaction for stent thrombosis or a composite of major adverse cardiac events related to the *CYP2C19**17 allele, although bleeding risk was not assessed.[19] In a study performed by Lewis *et al.*, *CYP2C19**17 was in significant linkage disequilibrium with *CYP2C19**2 and was not found to be an independent predictor for pharmacokinetic and pharmacodynamic outcome in patients treated with clopidogrel.[20] The effect found for the *17 allele was considered to be mostly, if not entirely, derived from non-independence with the *CYP2C19**2 variant. Our data supports this hypothesis, while no significant differences in thrombotic or bleeding outcomes were found according to *CYP2C19**17 genotype. Therefore, our data do not support routine testing of *CYP2C19**17 to guide antiplatelet therapy in clinical practice.

14

Our findings are clinically relevant for different reasons. Although P2Y$_{12}$ inhibitors are primarily initiated to reduce thrombotic risk, the inevitable bleeding risk associated with the use of those agents is clearly associated with morbidity and mortality.[13] Therefore, the use of a tailored antiplatelet strategy capable of balancing the bleeding and thrombotic risks is expected to improve overall clinical outcome. While trials studying the use of platelet function testing in tailoring antiplatelet therapy failed to show superiority compared to standard treatment and is therefore not routinely recommended, our results add to the growing body of evidence that *CYP2C19* genotype can be used to tailor antiplatelet therapy.[10, 21,22] Recently published results from a large prospective multicenter study in France by Hulot *et al.* also demonstrate that the availability of genetic results within days after STEMI can have a major impact on the prescription patterns of cardiologists.[23] Additionally, because the use of ticagrelor and prasugrel is far more expensive compared to generic clopidogrel, a strategy in which two thirds of patients can be treated with generic clopidogrel without losing the efficacy of the antiplatelet treatment is likely to be cost-effective.[24] A cost-effectiveness analysis was also one of the primary objectives of the POPular Genetics trial and is expected to be published in the near future. Finally, ticagrelor is associated with side effects like dyspnea, which is a frequent reason to switch or even discontinue antiplatelet therapy,[25] while prasugrel needs a dose adjustment for the elderly and low body weight patients and is contra-indicated in patients with previous stroke or transient ischemic attack.[4]

Some limitations to our analysis need to be mentioned. First, it is a subanalysis of a larger trial and therefore not powered for its primary outcome. In particular in the analysis of *CYP2C19**17, the relatively low number of patients led us to the use of a dominant model (combining patients with *1/*17 and *17/*17 genotype) instead of a recessive model (comparing *17 homozygous patients to *1/*1 and *1/*17 patients). A possible effect limited

15

to patients homozygous for the *CYP2C19**17 allele might have been underestimated or missed. Second, we only tested for the *2 and *3 LoF alleles, since the prevalence of other LoF alleles is very small (<1% for all LoF alleles combined). Therefore, a handful of clopidogrel treated patients might now be identified as not carrying a LoF allele, while in fact they do. Third, due to the low number of patients treated with prasugrel we cannot draw any conclusions for this drug specifically. While the recently published ISAR-REACT 5 trial showed superiority of prasugrel over ticagrelor in patients with acute coronary syndrome, further research is needed to evaluate if our findings also apply to patients treated with prasugrel.[26]

Conclusion

In patients after primary PCI not carrying a *CYP2C19* loss-of-function allele, the use of clopidogrel compared to ticagrelor or prasugrel was associated with lower bleeding rates, without significant increase in thrombotic events. No effect on clinical outcome was found for the *CYP2C19**17 gain-of-function polymorphism.

Disclosures

Dr. van 't Hof reports grants from Medtronic, Astra Zeneca and Sanofi and personal fees from Astra Zeneca and AMGEN; Dr. Barbato reports personal fees from BOSTON SCIENTIFIC, ABBOTT VASCULAR and GE; Dr. Asselbergs report grants from UCL Hospitals NIHR Biomedical Research Center; Dr. Ten Berg reports grants from Astra Zeneca and personal fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, the Medicines Company, Accumetrics, Boehringer-Ingelheim, Bayer, BMS, Pfizer and Ferrer.

Supplementary Materials:

Supplemental Tables I-II

References:

1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119-77.

2. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2016; 134: e123-55.

3. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.

4. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.

5. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, Van der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303: 754-62.

6. Niu X, Mao L, Huang Y, Baral S, Li JY, Gao Y, Xia YP, He QW, Wang MD, Li M, et al. CYP2C19 polymorphism and clinical outcomes among patients of different races

treated with clopidogrel: A systematic review and meta-analysis. J Huazhong Univ Sci Technolog Med Sci 2015;35:147-156

7. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-17

8. Li Y, Tang HL, Hu YF, Xie HG. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost 2012;10:199-206

9. Moon JY, Franchi F, Rollini F, Rivas Rios JR, Kureti M, Cavallari LH, Angiolillo DJ. Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Rev Clin Pharmacol 2018;11:151-164

10. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, Van 't Hof AWJ, Van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, et al. A genotype-guided strategy for oral P2Y$_{12}$ inhibitors in primary PCI. N Engl J Med 2019;381:1621-1631

11. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted J, Husted S, Katus H, Steg PG, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320-8

12. Puymirat E, Cayla G, Cottin Y, Elbaz M, Henry P, Gebraud E, Lemesle G, Popovic B, Labèque JN, Roubille F, et al. Twenty-year trends in profile management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015. Am Heart J 2019;214:97-106

13. Généreux P, Giustino G, Witzenbichler B, Weisz G, Stuckey TD, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol 2015;66:1036-1045

14. Bergmeijer TO, Janssen PWA, Schipper JC, Qaderdan K, Ishak M, Ruitenbeek RS, Asselbergs FW, Van 't Hof AW, Dewilde WJ, Spanó F, et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the patient outcome after primary PCI (POPular) Genetics study. Am Heart J 2014;168:16-22.e.1

15. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376:1312-19

16. Perreira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, Bell M, Bae JH, Jeong MH, Chavez I, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention. JAMA 2020;324:761-771

17. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, Von Beckerath N, Kastrati A. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010;121:512-518

18. Zabalza M, Subirana I, Sala, J, Lluis-Ganella C, Lucas G, Toma's M, Masiá R. Marrugat J, Brugada R, Elosua R. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular

outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012; 98:100-108

19. Bauer T, Bouman HJ, Van Werkum JW, Ford NF, Ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011;343:d4588

20. Lewis JP, Stephens SH, Horenstein RB, O'Connell JR, Ryan K, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Mitchell BD, et al. The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost 2013;11:1640-1646

21. Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-2109

22. Sibbing D, Aradi D, Jacobshagen C, Gross L, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, Komocsi A, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomized, open-label, multicenter trial. Lancet 2017;390:1747-57

23. Hulot JS, Chevalier B, Belle L, Cayla G, Khalife K, Funck F, Berthier R, Piot C, Tafflet M, Montalescot G. Routine *CYP2C19* genotyping tot adjust thienopyridine treatment after primary PCI for STEMI: Results of the GIANT study. JACC Cardiovasc Interv 2020;13:621-30

24. Wang Y, Yan BP, Liew D, Lee VWY. Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome. Pharmacogenomics J 2018;18:113-120

25. Bergmeijer TO, Janssen PWA, Van Oevelen M, Van Rooijen D, Godschalk TC, Kelder JC, Deneer VHM, Serebruany VL, Ten Berg JM. Incidence and causes for early ticagrelor discontinuation: A "Real-World" Dutch Registry Experience. Cardiology 2017;138:164-168

26. Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019;381:1524-1534

Figure 1. Flowchart

Flowchart of patients included in the different sub group analyses**.** LoF: Loss-of-function.

Figure 2. Outcomes of clopidogrel in *1/*1 patients versus *17 carriers

Kaplan-Meier curves for the thrombotic outcome (1A) defined as cardiovascular death, myocardial infarction, stent thrombosis and stroke, and the bleeding outcome (1B), defined as PLATO major and minor bleeding in clopidogrel treated *1/*1 patients versus *17 carriers. P-values are adjusted for baseline differences.

Figure 3. Outcomes of clopidogrel in patients without LoF versus ticagrelor or prasugrel treated patients

Kaplan-Meier curves for the thrombotic outcome (2A), defined as cardiovascular death, myocardial infarction, stent thrombosis and stroke, and the bleeding outcome (2B), defined as PLATO major and minor bleeding in clopidogrel treated patients without a loss-of-function allele versus ticagrelor or prasugrel treated patients. P-values are adjusted for baseline differences.

Table 1 Baseline characteristics of clopidogrel treated patients according to

CYP2C19*17 carrier status

	CYP2C19*1/*1 N = 420	*CYP2C19**17 carriers N = 312	p-value
Age (Years, mean ± SD)	61.2 ± 10.8	62.8 ± 11.2	0.06
Female sex (n, %)	105 (25.0)	89 (28.5)	0.33
BMI (kg/m2, mean ± SD)	27.7 ± 9.85	27.1 ± 4.14	0.28
Creatinine clearance <60ml/minute/1.73m2 at baseline* (n, %)	39 (9.4)	29 (9.4)	1.0
History (n, %)			
Current smoker	199 (48.2)	126 (40.6)	0.05
Hypertension	174 (41.4)	127 (40.7)	0.90
Dyslipidemia	83 (19.8)	63 (20.2)	0.96
Diabetes Mellitus	43 (10.2)	32 (10.3)	1.0
Coronary artery disease	47 (11.2)	32 (10.3)	0.78
Peripheral arterial disease	17 (4.1)	11 (3.5)	0.87
Stroke	7 (1.7)	3 (1.0)	0.53
Bleeding	9 (2.1)	8 (2.6)	0.90
Discharge medication (n, %)			
Aspirin	404 (96.4)	302 (96.8)	0.944
$P2Y_{12}$ inhibitor after discharge			
Clopidogrel	420 (100)	312 (100)	

Vitamin K antagonist	26 (6.2)	13 (4.2)	0.30
Novel anticoagulant	6 (1.4)	8 (2.6)	0.41
ACE inhibitor	320 (76.4)	227 (72.8)	0.30
ATII antagonist	42 (10.0)	33 (10.6)	0.90
Beta Blocker	370 (88.3)	276 (88.5)	1.0
Statin	408 (97.4)	300 (96.2)	0.47
Proton pump inhibitor	332 (79.2)	247 (79.2)	1.0
Procedural characteristics			
Access site			0.54
Femoral	133 (31.7)	106 (34.2)	
Radial	286 (68.3)	204 (65.8)	
Multivessel disease	205 (48.8)	168 (53.8)	0.20
Stent			
None	10 (2.4)	4 (1.3)	0.42
Bare Metal Stent	21 (5.0)	20 (6.4)	0.51
Biovascular Scaffold	4 (0.1)	3 (1.0)	1.0
Drug Eluting Stent	393 (93.6)	292 (93.6)	1.0
Ostial Lesion	28 (6.7)	20 (6.5)	1.0
Bifurcation lesion	82 (19.6)	64 (20.6)	0.79
Total stent length	27.6 (14.0)	26.6 (13.3)	0.33

BMI: Body mass index.

* Creatinine clearance was calculated with the use of the Chronic Kidney Disease

Epidemiology Collaboration (CKD-EPI) formula.

Table 2 Baseline characteristics of clopidogrel in patients without *CYP2C19**2 or *3 LoF allele versus ticagrelor or prasugrel in all patients (irrespective of *CYP2C19* genotype)

	Clopidogrel (no LoF allele) N = 821	Ticagrelor & prasugrel N = 1608	p-value
Age (Years, mean ± SD)	62.0 ± 10.9	61.3 ± 11.3	0.14
Female sex (n, %)	224 (27.3)	388 (24.1)	0.10
BMI (kg/m2, mean ± SD)	27.5 ± 7.66	27.2 ± 4.22	0.32
Creatinine clearance <60ml/minute/1.73m2 at baseline* (n, %)	75 (9.2)	148 (9.2)	1.0
History (n, %)			
Current smoker	372 (45.9)	738 (46.3)	0.90
Hypertension	348 (42.4)	655 (40.7)	0.46
Dyslipidemia	172 (21.0)	332 (20.7)	0.91
Diabetes Mellitus	89 (10.8)	186 (11.6)	0.64
Coronary artery disease	82 (10.0)	157 (9.8)	0.92
Peripheral arterial disease	31 (3.8)	41 (2.6)	0.12
Stroke	10 (1.2)	20 (1.2)	1.0
Bleeding	19 (2.3)	33 (2.1)	0.78
Discharge medication (n, %)			
Aspirin	794 (96.8)	1578 (98.3)	0.03
P2Y$_{12}$ inhibitor after discharge			
Clopidogrel	821 (100)	0 (0.0)	

Prasugrel 10mg	0 (0.0)	38 (2.4)	
Prasugrel 5mg	0 (0.0)	5 (0.3)	
Ticagrelor	0 (0.0)	1565 (97.3)	
Vitamin K antagonist	42 (5.1)	22 (1.4)	<0.001
Novel anticoagulant	14 (1.7)	3 (0.2)	<0.001
ACE inhibitor	618 (75.4)	1252 (78.0)	0.16
ATII antagonist	77 (9.4)	147 (9.2)	0.91
Beta Blocker	726 (88.5)	1435 (89.4)	0.56
Statin	795 (97.0)	1560 (97.2)	0.83
Proton pump inhibitor	656 (80.0)	1217 (75.8)	0.02
Procedural characteristics			
Access site			0.23
Femoral	249 (31.1)	444 (28.2)	
Radial	552 (68.9)	1127 (71.7)	
Multivessel disease	402 (49.1)	739 (46.0)	0.17
Stent			
None	14 (1.7)	25 (1.6)	0.91
Bare Metal Stent	44 (5.4)	62 (3.9)	0.11
Biovascular Scaffold	8 (1.0)	17 (1.1)	1.0
Drug Eluting Stent	766 (93.3)	1520 (94.5)	0.26
Ostial Lesion	53 (6.8)	85 (5.6)	0.27
Bifurcation lesion	154 (19.8)	287 (18.7)	0.59
Total stent length	27.3 ± 13.7	28.8 ± 17.8	0.07

BMI: Body mass index. LoF: loss-of-function.

* Creatinine clearance was calculated with the use of the Chronic Kidney Disease

Epidemiology Collaboration (CKD-EPI) formula

Table 3. Outcomes in clopidogrel treated patients according to *CYP2C19**17 carrier status

Outcome	*CYP2C19* *1/*1 (N=420)	*CYP2C19* **17 carriers (N=312)	Unadjusted Hazard ratio (95% CI)	Adjusted Hazard ratio (95% CI) *	Adjusted p-value
		No. of patients (%)			
Thrombotic outcomes					
Cardiovascular death, MI, ST, and stroke	16 (3.8)	12 (3.8)	1.01 (0.48 – 2.13)	0.95 (0.45 – 2.02)	0.90
Cardiovascular death	1 (0.2)	3 (1.0)	4.04 (0.42 – 38.8)	-	0.23
Myocardial infarction	12 (2.9)	6 (1.9)	0.67 (0.25 – 1.79)	-	0.43
Stroke	3 (0.7)	3 (1.0)	1.34 (0.27 – 6.66)	-	0.72
ST	1 (0.2)	1 (0.3)	1.35 (0.08 – 21.6)	-	0.83
Bleeding outcomes					
PLATO major and minor bleeding	47 (11.2)	29 (9.3)	0.82 (0.52 – 1.31)	0.74 (0.48 – 1.18)	0.21
PLATO major	10 (2.4)	8 (2.6)	1.08 (0.43 – 2.74)	0.96 (0.38 – 2.43)	0.93
PLATO minor	37 (8.8)	22 (7.1)	0.79 (0.47 – 1.34)	0.73 (0.43 – 1.24)	0.24

Only clopidogrel treated patients with normal CYP2C19 metabolism were included fort his analysis (i.e. *1/*1, *1/*17 & *17/*17). MI: Myocardial infarction, PLATO: platelet inhibition and patient outcome, ST: stent thrombosis.

* Significant variables are shown in Table S1 in the supplementary appendix.

Table 4. Outcomes of clopidogrel in patients without *CYP2C19**2 or *3 loss-of-function allele versus ticagrelor or prasugrel irrespective of *CYP2C19* genotype

Outcome	Clopidogrel (N=821)	Ticagrelor or prasugrel (N=1608)	Unadjusted Hazard ratio (95% CI)	Adjusted Hazard ratio (95% CI) *	Adjusted p-value
		No. of patients (%)			
Thrombotic outcomes					
Cardiovascular death, MI, ST, and stroke	28 (3.4)	41 (2.5)	1.35 (0.83 – 2.18)	1.14 (0.68 – 1.90)	0.62
Cardiovascular death	4 (0.5)	8 (0.5)	0.98 (0.29 – 3.25)	0.44 (0.11 – 1.84)	0.26
Myocardial infarction	18 (2.2)	25 (1.6)	1.42 (0.77 – 2.59)	1.47 (0.79 – 2.77)	0.23
Stroke	6 (0.7)	13 (0.8)	0.90 (0.34 – 2.38)	0.82 (0.29 – 2.34)	0.71
ST	2 (0.2)	3 (0.2)	1.30 (0.22 – 7.81)	-	0.77
Bleeding outcomes					
PLATO major and minor bleeding	81 (9.9)	188 (11.7)	0.84 (0.64 – 1.09)	0.74 (0.56 – 0.96)	0.03
PLATO major	19 (2.3)	33 (2.1)	1.13 (0.64 –	1.00 (0.55 –	1.0

			1.98)	1.81)	
PLATO minor	63 (7.7)	159 (9.9)	0.77 (0.57 – 1.03)	0.69 (0.51 – 0.93)	0.02

Analysis of clopidogrel treated patients without loss-of-function allele versus ticagrelor and prasugrel treated patients, irrespective of CYP2C19 metabolizer status. MI: Myocardial infarction, PLATO: platelet inhibition and patient outcome, ST: stent thrombosis.

* Significant variables are shown in Table S2 in the supplementary appendix.

Table 5. Outcomes of the two sensitivity analyses

Outcome	Clopidogrel	Ticagrelor or prasugrel	Unadjusted Hazard ratio (95% CI)	Adjusted Hazard ratio (95% CI) *	Adjusted p-value
	No. of patients (%)				
Clopidogrel (n=821) vs. ticagrelor or prasugrel (n=729) in patients without LoF alleles					
Cardiovascular death, MI, ST, and stroke	28 (3.4)	21 (2.9)	1.19 (0.68 – 2.09)	1.11 (0.61 – 2.03)	0.72
PLATO major and minor bleeding	81 (9.9)	103 (14.1)	0.68 (0.51 – 0.91)	0.59 (0.44 – 0.80)	<0.001
Clopidogrel (n=821) vs. ticagrelor or prasugrel (n=1613), on-treatment analysis					
Cardiovascular death, MI, ST, and stroke	23 (2.8)	39 (2.4)	1.13 (0.68 – 1.89)	0.98 (0.56 – 1.70)	0.94
PLATO major and minor bleeding	72 (8.8)	177 (11.0)	0.76 (0.57 – 0.99)	0.68 (0.52 – 0.91)	0.008

Sensitivity analyses of clopidogrel treated patients without loss-of-function alleles versus ticagrelor and prasugrel treated patients. LoF: loss-of-function, MI: Myocardial infarction, PLATO: platelet inhibition and patient outcome, ST: stent thrombosis.

* Significant variables are shown in Table S2 in the supplementary appendix.

A

Thrombotic outcome

p = 0.90

N at risk

*1/*1 patients	420	410	408	408	408	406	404	404	404
*17 carriers	312	306	302	302	301	301	301	301	300

B

Bleeding outcome

p = 0.21

N at risk

*1/*1 patients	420	408	402	397	392	387	382	379	374
*17 carriers	312	306	300	296	291	290	288	286	285

A

Thrombotic outcome

N at risk									
Clopidogrel	821	805	799	799	798	796	794	794	793
Tica/prasu	1608	1592	1582	1580	1578	1573	1571	1569	1567

p = 0.62

B

Bleeding outcome

N at risk									
Clopidogrel	821	801	788	778	768	762	755	750	743
Tica/prasu	1608	1549	1524	1504	1487	1473	1455	1443	1425

p = 0.03